Case Report

Malignant phyllodes tumor of the breast with metastases to the lungs: A case report and literature review

Edvin Ostapenko, MD, Arvydas Burneckis, MD, PhD, Andrej Ostapenko, MD, Audronė Skaisgirytė, MD, Valerijus Ostapenko, MD, PhD

A National Cancer Institute, Santariskiu str. 1, Vilnius LT-08660, Lithuania
B Faculty of Medicine, Vilnius University, Vilnius, Lithuania

ABSTRACT

Phyllodes tumors (PTs) are rare fibroepithelial neoplasms of the breasts. Approximately 10%-15% of PTs are malignant, and 9%-27% of patients with malignant PTs, develop metastatic disease. The lungs are the most common target organ for distant metastasis of PT. We report a case of 44-year-old female with a malignant PT. It had recurred locally 3 times, and 3 relapses occurred 13 months after the first diagnosis, presenting multiple metastases to the lungs by CT scan. The patient underwent radiation therapy, and palliative chemotherapy with doxorubicin was initiated. Two courses of doxorubicin therapy were administered, but the patient expired 16 months after PT diagnosis. We present a rare case of malignant PT with local recurrences, lung metastases, and poor patient outcome. Although malignant breast PTs have an unfavorable prognosis, adjuvant radiotherapy combined with margin-negative resection may be associated with decreased local recurrence and distant metastasis rates. Future research should include randomized clinical trials or well-designed prospective matched studies to clarify the effectiveness of treatments of PTs.

Copyright © 2022 The Authors. Published by Elsevier Inc. on behalf of University of Washington. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

Introduction

Phyllodes tumors (PTs) are rare neoplastic lesions that are comprised of both stromal and epithelial components, and they account for approximately 0.3%-1% of breast tumors in women [1]. The term “phyllodes” which means leaf-like, describes the typical papillary projections that are seen on pathologic examination. They were originally called “cystosarcoma phyllodes” by Johannes Müller in 1838 [2]. World Health Organization (WHO) presented classification of tumors of the breast, introduced the term phyllodes tumors, criteria for diagnosis and grading of PT. PTs are subdivided into benign (60%-75%), borderline (15%-20%), or malignant (10%-20%).

✩✩✩ Competing Interests: All authors declare no conflict of interest.
✩✩✩✩ Funding: The authors received no financial support for the research, authorship and publication of this article.
* Corresponding author.
E-mail address: valerijus.ostapenko@gmail.com (V. Ostapenko).
https://doi.org/10.1016/j.radcr.2022.07.037
1930-0433© 2022 The Authors. Published by Elsevier Inc. on behalf of University of Washington. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
based on the assessment of 5 features: the degree of stromal cellular atypia; the mitotic activity per 10 high-power fields (HPFs); infiltrative or circumscribed tumor margins; the presence or absence of stromal overgrowth (ie, the presence of pure stroma devoid of epithelium); and the nature of the tumor border [3]. The average tumors size ranges from 4 to 5 cm. When PTs are larger than 10 cm in diameter, they have been classified as “giant” PTs, which account for about 20% of all PTs [4]. In 1931, the first case of a malignant PT with metastases to the lungs was reported, which revealed that these tumors could exhibit malignant behavior [5]. Recent literature reports that 10%-15% of PTs are malignant and approximately 9%-27% of patients with malignant phyllodes tumor have metastasis to distant organs with spreading hematogenously to most frequent sites as lungs, bones, brain, and liver [6]. Recurrence or metastasis of breast PTs predicts a shorter survival time, less than 2 years after diagnosis [7–21].

In this report, we describe a rare case of malignant PT of the breast with local recurrences and subsequent metastases to the lungs, we provide a review of the literature, and we discuss treatment modalities.

Case report

A 44-year-old female patient from Lithuania presented to the National Cancer Institute (NCI) complaining of a mass in her left breast that had grown rapidly in the last 12 months. The patient experienced menarche at the age of 16, gave birth to 2 children. No significant signs were observed in the patient’s medical or family history. On physical examination, the patient was a well-developed woman with an obvious left-sided breast mass. At the time of presentation, the left breast mass measured 11 cm × 7 cm × 8 cm in greatest dimension. Axillary, mediastinal, or clavicular lymphadenopathy was not observed. The patient’s right breast was normal upon palpation. Mammography showed a high-density, smoothly contoured masses with well-circumscribed margins in the left breast measuring 7.8 × 4.3 cm, 4.5 × 2.8 cm, and 3.6 × 2.8 cm (Fig. 1). A core needle biopsy was performed on the same day. The left breast biopsy results revealed malignant neoplasms with carcinomatous and sarcomatous elements. The cells showed marked pleomorphism with >10 mitoses/10HPF. The patient underwent partial mastectomy. Detailed descriptions are shown in (Table 1). Pathological examination confirmed a malignant PT (Fig. 2). Postoperative recovery was without complications with a well-healing wound.

Three months after the surgery, the patient became aware of a soft tissue mass growing at the partial mastectomy scar. Upon physical examination, postsurgical changes consistent with a left partial mastectomy and a new parasternal 6 cm nonmobile, nontender mass fixed to the medial portion of the scar were observed. No palpable axillary lymphadenopathy was noted.

Core needle biopsy of the breast mass revealed recurrent malignant PT. The patient underwent left mastectomy. The postoperative recovery was uneventful. Pathological examination revealed recurrence of malignant phyllodes tumor with atypical osteoid formation (Fig. 3). After multidisciplinary dis-

Table 1 - Timeline

| Time  | Description                        | Treatment                        |
|-------|------------------------------------|----------------------------------|
| 2019.10 | Diagnosis of primary malignant phyllodes tumor | Partial mastectomy             |
| 2020.01 | Local recurrence                   | Mastectomy                       |
| 2020.02 |                                | Beginning the radiotherapy       |
| 2020.10 | The second local recurrence        | Axillary tumor with m. pectoralis major and m. serratus anterior resection |
| 2020.11 | Detection of lung metastasis. Third local recurrence | Beginning the chemotherapy |
| 2021.02 |                                | The patient expired              |

Phyllodes tumors of the breast are rare fibroepithelial neoplasms and exhibit a wide range of clinical behaviors. PT and fibroadenoma (FA) are both fibroepithelial lesions, but their management differs. FA may be safely followed without further investigation, whereas PT requires surgical excision. Multidisciplinary approach is very important to distinguish PT from FA in patients with diagnosed fibroepithelial lesions. There are rare cases documented in literature of a FA transformation to a PT. There are 2 possibilities that could account for a core biopsy proven FA being rediagnosed as a PT: the first possibility is misdiagnosis at core biopsy due to their overlapping pathologic appearance, or the second possibility, more rarely, the progression of a FA into a PT [22]. There is no accurate imaging or clinical predictor of which lesion will trans-

Discussion

Phyllodes tumors of the breast are rare fibroepithelial neoplasms and exhibit a wide range of clinical behaviors. PT and fibroadenoma (FA) are both fibroepithelial lesions, but their management differs. FA may be safely followed without further investigation, whereas PT requires surgical excision. Multidisciplinary approach is very important to distinguish PT from FA in patients with diagnosed fibroepithelial lesions. There are rare cases documented in literature of a FA transformation to a PT. There are 2 possibilities that could account for a core biopsy proven FA being rediagnosed as a PT: the first possibility is misdiagnosis at core biopsy due to their overlapping pathologic appearance, or the second possibility, more rarely, the progression of a FA into a PT [22]. There is no accurate imaging or clinical predictor of which lesion will trans-
Fig. 1 – Mammogram of the left breast. There is a high-density, smoothly contoured formations (7.8 × 4.3 cm, 4.5 × 2.8 cm, and 3.6 × 2.8 cm), with circumscribed margins in left region of the breast.

Fig. 2 – Malignant phylloid tumor with 2 distinct components: on the right side classical phylloid tumor with overgrowth of cellular stroma and intraductal leaf-like structures; on the left side diffuse sarcoma-type growth of highly atypical cells (HE staining).
form. The majority of PT occur in women between the ages of 35 and 55 years, whereas a FA is the most common solid breast mass in a woman under the age of 30 but can be seen in older women as well [22]. In men, phyllodes tumors usually occur in association with gynecomastia. PT is reported rarely in men [23]. PTs can be caused by genetic syndromes, such as Li-Fraumeni syndrome (germline TP53 mutation), which is related to breast cancers, brain tumors, soft tissue sarcomas, and rarely other types of tumors [24]. Malignant PTs have a higher risk of metastatic disease, whereas benign and borderline tumors demonstrate a proclivity for local recurrence and rarely metastasize [25]. Koh et al. [26] showed that a combination of large tumor size (≥90 mm) and the presence of malignant heterologous elements had a statistically significant association with the development of distant metastasis. Most frequently, malignant PTs metastasize to the lung, bones, brain, and liver [7–21]. Few rare distant metastatic sites are the adrenal glands [20], kidney [13], skin [27], ovary [28], heart [29], pleura [30], oral cavity [31], duodenum [32], pancreas [33], tonsillar [12], and para-aortic nodes [34]. Once patients with malignant PT develop metastasis, their prognosis is extremely poor. The median survival ranged from 5 to 30 months [35]. Our patient expired 16 months after the diagnosis of PT.

Surgery is the mainstay of treatment for breast PTs. Lu et al. [36] showed in a recent meta-analysis of 54 retrospective studies with 9234 patients that a positive surgical margin increased the risk of local recurrence: 8% for benign, 13% for borderline, and 18% for malignant PTs. Jang et al. [37] retrospectively reviewed 164 patients with PTs and found that the main prognostic factor for local recurrence of PTs was the presence of tumor cells on the resection margin. They also found, that the width of the resection margin did not confer
a local recurrence risk. According to the newest 3.2022 guidelines of the Nation Comprehensive Cancer Network (NCCN), the recommendation for the treatment of PT is local surgical excision with tumor-free margins of 1 cm or greater for malignant and borderline PT. Narrow surgical margins are not an absolute indication for mastectomy when partial mastectomy fails to achieve a margin width ≥1 cm. Total mastectomy is only necessary if negative margins cannot be obtained by lumpectomy or partial mastectomy. While for benign PT excisional biopsy includes complete mass removal, but without the intent of obtaining surgical margins. Since phyllodes tumors rarely metastasize to the ALNs, surgical axillary staging or ALN dissection is not necessary unless the lymph nodes are pathologic on clinical examination [24].

Currently, there is no consensus regarding the role of radiotherapy in malignant PT. Comprehensive Cancer Network (NCCN) 3.2022 guidelines recommend consideration of radiotherapy for malignant PTs only in the setting of local

| Author, year, country   | Age\(^a\) (years) | Tumor size (cm) | Distant metastasis | Adjuvant treatment | Mean survival (Month) |
|-------------------------|-------------------|-----------------|--------------------|--------------------|-----------------------|
| Basto et al. [7] 2021, Portugal | 57                | 25.8            | Lungs              | Radiotherapy, chemotherapy | 14+                        |
| Wang et al. [8] 2021, China | 26               | 19              | Lungs              | Radiotherapy        | 13+                        |
| Koukourakis et al. [9] 2021, Greece | 62           | 7.4             | Lungs              | Radiotherapy, chemotherapy | 24+                       |
| Moon et al. [10] 2019, Korea | 48               | 15              | Lungs              | Chemotherapy        | 36+                        |
| Le et al. [11] 2021, Vietnam | 57               | 8               | Lungs              | Chemotherapy        | N/A                        |
| Sera et al. [12] 2017, Japan | 57               | 10              | Lungs, tonsillar   | /                  | 8                          |
| Borowska et al. [13] 2015, Poland | 41               | 4               | Lungs, kidney, bones, liver | Radiotherapy, chemotherapy | 17                        |
| Nakamura et al. [14] 2020, Japan | 71              | 15              | Lungs              | /                  | 13+                        |
| Johnson et al. [15] 2016, USA | 66               | 16              | Lungs, bones, brain | Radiotherapy        | 14                          |
| Augustyn et al. [16] 2015, USA | 56              | 22              | Lungs              | Radiotherapy        | N/A                        |
| Gregston et al. [17] 2019, USA | 32              | 32              | Lungs, brain      | Chemotherapy        | 20                          |
| Abe et al. [18] 2020, Japan | 44               | 20              | Lungs              | Chemotherapy        | 4                           |
| Ganesh et al. [19] 2017, Canada | 43              | 3.5             | Lungs              | Radiotherapy, chemotherapy | 30                        |
| Khanal et al. [20] 2018, Nepal | 37              | 15              | Lungs, adrenal, brain | /                  | N/A                        |
| Singer et al. [21] 2013, USA | 43               | 19              | Lungs, bones      | Radiotherapy, chemotherapy | N/A                        |
| Our case, 2022, Lithuania | 44               | 11              | Lungs              | Radiotherapy, chemotherapy | 16                        |

\(^a\) – Age at diagnosis of primary phyllodes tumor. + – No information of death upon last follow up; N/A – not available.
recurrence (level 2 B evidence) [24]. However, Barth et al. [38] in a prospective, multi-institutional study, revealed that margin-negative resection combined with adjuvant radiotherapy is very effective for local control of borderline and malignant phyllodes tumors. According to Chao et al. [39] meta-analysis of 17 retrospective studies with 696 patients, found that radiotherapy is effective in achieving local disease control and preventing metastasis. Belkacemi et al. [40] reported that in 159 patients with malignant and borderline phyllodes tumors, radiotherapy significantly decreased local recurrence rate (P = .02). Accordingly, margin-negative resection combined with adjuvant radiotherapy could be the new gold standard for borderline and malignant PTs.

Adjuvant chemotherapy effects in PTs treatment are lacking because of insufficient data from large prospective studies. In our literature review of patient with distant metastasis to the lungs, the most frequent chemotherapy was with Doxorubicin and ifosfamide [7,10,17–19]. In 6 studies [8,12,14–16,20] adjuvant chemotherapy was not given due to controversial effects or patient’s request, detailed descriptions are shown in (Table 2). Moon et al. [10] showed complete remission of lung metastasis and no evidence of locoregional or distant metastasis 3 years after mastectomy with axillary lymph node dissection and adjuvant chemotherapy with doxorubicin and ifosfamide. Koukourakis et al. [9] revealed that the combination of cisplatin with nab-paclitaxel and liposomal doxorubicin chemotherapy had acceptable toxicity and was highly effective in eradicating metastatic lesions. Within 2 years of follow-up, the patients were free of disease and treatment-related toxicities. The Comprehensive Cancer Network (NCCN) guidelines recommend that treatment of distant metastasis with PT following the NCNN Soft Tissue Sarcoma Clinical Practice Guidelines version 2.2022. Preferred regimen: (doxorubicin, ifosfamide, mesna/ifosfamide, epirubicin, mesna) [24].

Conclusion

We present a rare case of malignant PT with local recurrences, lung metastases and poor patient outcome. Although malignant breast PTs have an unfavorable prognosis, adjuvant radiotherapy combined with margin-negative resection may be associated with decreased local recurrence and distant metastasis rates. Future research should include randomized clinical trials or well-designed prospective matched studies to clarify the effectiveness of treatments of PTs.

Author contribution

Drs E.O. and V.O. had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: E.O. and A.O. Acquisition, analysis, or interpretation of data: All authors. Drafting of the manuscript: E.O. and A.O. Critical revision of the manuscript for important intellectual content: all authors. Study supervision: V.O. and A.B.

Ethical approval

Ethical approval was not required for this study.

Data availability

The data used to support the findings of this study are included within the article.

REFERENCES

[1] Zhang Y, Kleer CG. Phyllodes tumor of the breast: histopathological features, differential diagnosis, and molecular/genetic updates. Arch Pathol Lab Med 2016;140(7):665–71. doi:10.5858/arpa.2016-0042-RA.
[2] Müller J. Über den feinern bau und die formen der krankhaften geschwulste, Vol. 1. Berlin, Germany: Reimer; 1838. p. 54–60.
[3] Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, Vijver MJ, editors. World Health Organization classification of tumours of the breast. Lyon: International Agency for Research on Cancer (IARC); 2012.
[4] Mishra SP, Tiwary SK, Mishra M, Khanna AK. Phyllodes tumor of breast: a review article. ISRN Surg 2013;2013:361469. doi:10.1155/2013/361469.
[5] Lee BJ, Pack GT. Giant intracanalicular myxoma of the breast: the so-called cystosarcoma phyllodes mammae of Johannes Muller. Ann Surg 1931;93(1):250–68. doi:10.1097/00000658-193101000-00034.
[6] Treves N. A study of cystosarcoma phyllodes. Ann N Y Acad Sci 1964;114(2):922–36.
[7] Basto R, Pereira TC, Rei L, Salgueiro FR, Magalhães J, Sousa MJ, et al. Giant metastatic breast phyllodes tumour with an elusive diagnosis: a case report and literature review. Eur J Case Rep Intern Med 2021;2(8):002763. doi:10.12890/2021_002763.
[8] Wang X, Xie L, Hu W, Yan J, Qian X, Zhu L. Apatinib treatment is effective for metastatic malignant phyllodes tumors of the breast: a case report. BMC Womens Health 2021;21:238. doi:10.1186/s12905-021-01359-5.
[9] Koukourakis IM, Zygojannii A, Koulourlias V, Koukourakis MI. Successful treatment of a locally recurrent and metastatic malignant phyllodes tumor with accelerated radiotherapy and nab-paclitaxel, cisplatin, and liposomal doxorubicin chemotherapy. Chemotherapy 2021;66(3):82–6. doi:10.1159/000517246.
[10] Moon SH, Jung JH, Lee J, Kim WW, Park HY, Lee JW, et al. Complete remission of giant malignant phyllodes tumor...
with lung metastasis. Medicine (Baltimore) 2019;98(22):e15762. doi: 10.1097/MD.0000000000015762.

[11] Le QH, Mai VT. Malignant phyllodes tumor with synchronous metastases to axillary lymph nodes, lung at the presentation: a case report and literature review. J Surg Case Rep 2021;2021(7):rjab302. doi: 10.1055/jscr/rjab302.

[12] Sera T, Kashigawa S, Takashima T, Asano Y, Goto W, limori N, et al. Multiple metastatic malignant phyllodes tumor of the breast with tonsillar metastasis: a case report. BMC Res Notes 2017;10:55. doi: 10.1186/s13104-017-2375-5.

[13] Karczmarek-Borowska B, Bukal A, Spyrek-Kapilka K, Ksiazek M, Filipowska J, Gradalska-Lampart M. A rare case of breast malignant phyllodes tumor with metastases to the kidney. Medicine (Baltimore) 2015;94(33):e1312. doi: 10.1097/MD.000000000001312.

[14] Nakamura S, Goto T, Nara S, Kawahara Y, Yashiro S, Kano S, et al. Pure ground glass opacity (GGO) on chest CT: a rare presentation of lung metastasis of malignant phyllodes tumor. Breast Cancer 2020;27(6):1187–90. doi: 10.1007/s12282-020-01122-y.

[15] Johnson ED, Gulbahce E, McNally J, Buys SS. Malignant phyllodes tumor presenting in bone, brain, lungs, and lymph nodes. Case Rep Oncol 2016;9(3):861–8. doi: 10.1159/000453660.

[16] Augustyn A, Sahoo S, Wooldridge RD. Large malignant phyllodes tumor of the breast with metastases to the lungs. Rare Tumors 2015;7(2):69–72. doi: 10.4081/rt.2015.5684.

[17] Gregston AP, Metter DM, Osborne CRC, Pippen J. Giant malignant phyllodes tumor with metastasis to the brain. Proc (Baylor Univ Med Cent) 2019;32(1):116–18. doi: 10.1002/pnum.21521207.

[18] Abe H, Teramoto A, Takei Y, Tanaka Y, Yoneda G. Malignant phyllodes tumor of the breast with rapid progression: a case report. Surg Case Rep. 2020;6:308. doi: 10.1186/s40792-020-00086-8.

[19] Ganesh V, Lee J, Wan BA, Rakovitch E, Vespurini D, Slodkowska E, et al. Palliative treatment of metastatic phyllodes tumors: a case series. AME Case Rep 2017;1:9. doi: 10.21037/acr.2017.12.01.

[20] Khanal S, Singh YP, Bhandari A, Sharma R. Malignant phyllodes tumor with metastases to lung, adrenal and brain: a rare case report. Ann Med Surg 2018;36:115–17. doi: 10.1016/j.amjsurg.2018.10.030.

[21] Singer A, Tesley J, Velazquez-Vega J, Yepes M. Unusual aggressive breast cancer: metastatic malignant phyllodes tumor. J Radiol Case Rep 2013;7(2):24–37. doi: 10.3941/jrcr.v7i2.1430.

[22] Sanders LM, Daigle ME, Tortora M, Panasiti R. Transformation of benign fibroadenoma to malignant phyllodes tumor. Acta Radiol Open 2015;4(7) 2058460115592061. doi: 10.1177/2058460115592061.

[23] Nielsen VT, Andreasen C. Phyllodes tumour of the male breast. Histopathology 1987;11(7):761–2. doi: 10.1111/j.1365-2559.1987.tb02690.x.

[24] Recently Updated Guidelines. Breast cancer version 3.2022. NCCN. Accessed May 31, 2022. Available at: https://www.nccn.org/guidelines/recently-published-guidelines.

[25] Tan BY, Acs G, Apple SK, Badve S, Bleiweiss IJ, Brogi E, et al. Phyllodes tumours of the breast: a consensus review. Histopathology 2016;68(1):5–21. doi: 10.1111/his.12876.

[26] Koh VCY, Thike AA, Nasir NDM, Yip GWC, Bay BH, Tan PH. Size and heterologous elements predict metastases in malignant phyllodes tumours of the breast. Virchows Arch 2018;472(4):615–21. doi: 10.1007/s00428-017-2257-1.

[27] Hawkins RE, Schofield JB, Fisher C, Wiltshaw E, McKinna J. The clinical and histologic criteria that predict metastases from cystosarcoma phylloides. Cancer 1992;69(1):141–7. doi: 10.1002/1097-0142(19920101)69:1<141::aid-cncr2822609215>3.0.co;2-1.

[28] Durga G, Gandhi JS, Mehta A. Malignant phyllodes tumor metastatic to bilateral ovaries: a Krakenberg-like presentation. J Cancer Res Ther 2018;14(5):1138–41. doi: 10.4103/jcrt.JCRT_612_18.

[29] Yoshidaya F, Hayashi N, Takahashi K, Suzuki K, Akiyama F, Ishiyama M, et al. Malignant phyllodes tumor metastasized to the right ventricle: a case report. Surg Case Rep. 2015;1:1–121. doi: 10.1186/s40792-015-0121-6.

[30] Suriyani S, Sharma R, Narasimhan M, Shamuganathan A, Rajendran A. A case of pleuroparenchymal metastasis: rare aetiology. J Clin Diagn Res 2016;10(4):OD03–5. doi: 10.7860/JCDR/2016/16532.7590.

[31] Roa MLS, Ruiz Godoy Rivera LM, Vela Chávez T, Pérez Sánchez M, Meneses García A. Breast malignant phyllodes tumour metastasizing to soft tissues of oral cavity. Clin Transl Oncol 2007;9(4):258–61. doi: 10.1007/s12094-007-0049-9.

[32] Asoglu O, Karanlik H, Barbaros U, Yanar H, Kapran Y, Kecer M. Malignant phyllode tumor metastatic to the duodenum. World J Gastroenterol 2006;12(10):1649–51. doi: 10.3748/wjg.v12.i10.1649.

[33] Wei J, Tan Y-T, Cai Y-C, Yuan Z-Y, Yang D, Wang S-S, et al. Predictive factors for the local recurrence and distant metastasis of phyllodes tumors of the breast: a retrospective analysis of 192 cases at a single center. Chin J Cancer 2014;33(10):492–500. doi: 10.5732/jcij.cj14.10048.

[34] Ramakant P, Selvamani, Therese MM, Paul MJ. Metastatic malignant phyllodes tumor of the breast: an aggressive disease—analysis of 7 cases. Indian J Surg Oncol 2015;6(4):363–9. doi: 10.11193/ijso.2015-0397-9.

[35] B AV, Clark BD, Goldberg JJ, Hoque LW, Bernik SF, Flynn LW, et al. Clinicopathologic features and long-term outcomes of 293 phyllodes tumors of the breast. Ann Surg Oncol 2007;14(10):2961–70. doi: 10.1245/s10434-007-9439-2.

[36] Lu Y, Chen Y, Zhu L, Cartwright P, Song E, Jacobs L, et al. Local recurrence of benign, borderline, and malignant phyllodes tumors of the breast: a systematic review and meta-analysis. Ann Surg Oncol 2019;26(5):1263–75. doi: 10.1007/s10434-018-07134-5.

[37] Jang JH, Choi M-Y, Lee SK, Kim S, Kim J, Lee J, et al. Clinicopathologic risk factors for the local recurrence of phyllodes tumors of the breast. Ann Surg Oncol 2012;19(8):2612–17. doi: 10.1245/s10434-012-2307-5.

[38] Barth RJ, Wells WA, Mitchell SE, Cole BF. A prospective, multi-institutional study of adjuvant radiotherapy after resection of malignant phyllodes tumors. Ann Surg Oncol 2009;16(8):2288–94. doi: 10.1245/s10434-009-0489-2.

[39] Chao X, Chen K, Zeng J, Bi Z, Guo M, Chen Y. Adjuvant radiotherapy and chemotherapy for patients with breast phyllodes tumors: a systematic review and meta-analysis. BMC Cancer 2019;19(1):372. doi: 10.1186/s12885-019-5585-5.

[40] Belkacemi Y, B G, M H, Ray-Coquard I, Magné N, Malard Y, Lacroix M, Gutierrez C, Senkus E, Christie D. Phyllodes tumor of the breast. Int J Radiat Oncol Biol Phys 2008;70(2):492–500. doi: 10.1016/j.ijrobp.2007.06.059.